secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2026-08-06T20:07:36+00:00
Accession:  0001213900-26-086136
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals shareholders approve reverse stock split, equity plan amendment, and management success fee
--------------------------------------------------------------------------------

- Reverse stock split approved at ratio of 1:5 to 1:10, as determined by board.
- Equity plan amended to increase shares available by 800,000.
- Success fee approved: 5% of deal proceeds between $40M-$100M, 6% above $100M, for change of control or sale of Arakoda.
- Five directors elected: Geoffrey Dow, Eric Francois, Cheryl Xu, Stephen Toovey, Paul Field.
- Ratification of RBSM LLP as independent auditor for FY 2026 approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/0001213900-26-086136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-086136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer